Optimi Health Corp.
OPTHHealthcare|Drug Manufacturers - Specialty & Generic|CA
$2.34
-0.05 (-2.09%)
Tangible Book / Share
$4.10
Cash / Share
$3.04
Financials
Financial Snapshot
Market Cap
$13.4M
Enterprise Value
$10.8M
Revenue (TTM)
$134.2K
Net Income (TTM)
-$6.2M
Cash & Investments
$9.2M
Net Cash
$5.6M
Free Cash Flow (TTM)
-$4.5M
Operating CF (TTM)
-$4.4M
Debt/Equity
0.29
Cash Runway & Burn Rate
Cash on Hand
$9.2M
Quarterly Burn
$1.1M
Monthly Burn
$363.0K
Est. Runway
~8.5 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.5M | $12.4M | $1.9M | $1.3M | $103.7K | $1.1M | $9.2M | |
| Operating Cash Flow | -$143.4K | -$6.0M | -$4.6M | -$3.6M | -$4.3M | -$2.6M | -$4.4M | |
| Free Cash Flow | -$898.3K | -$11.0M | -$11.7M | -$4.4M | -$4.4M | -$2.7M | -$4.5M | |
| Capital Expenditure | -$754.8K | -$4.9M | -$7.2M | -$804.2K | -$152.4K | -$88.4K | -$103.1K | |
| Financing Cash Flow | $5.4M | $19.2M | $1.2M | $3.8M | $3.2M | $3.8M | $13.6M |
R&D Spending
R&D (TTM)
$314.2K
R&D Intensity
234.2%
R&D Growth vs Prior
-9.8%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $80.7K | $181.1K | $389.9K | $426.9K | $134.2K | |
| R&D Expense | $0.00 | $240.9K | $133.2K | $152.1K | $144.5K | $348.2K | $314.2K | |
| R&D % of Revenue | — | — | 165.1% | 84.0% | 37.1% | 81.6% | 234.2% | |
| SG&A | $483.4K | $5.1M | $6.1M | $3.9M | $4.0M | $2.7M | $2.9M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $80.7K | $181.1K | $389.9K | $426.9K | $134.2K | |
| Cost of Revenue | $0.00 | $0.00 | $26.8K | $338.1K | $118.9K | $2.5M | $1.1M | |
| Gross Profit | $0.00 | $0.00 | $53.9K | -$157.0K | $270.9K | -$2.1M | -$938.0K | |
| R&D | $0.00 | $240.9K | $133.2K | $152.1K | $144.5K | $348.2K | $314.2K | |
| SG&A | $483.4K | $5.1M | $6.1M | $3.9M | $4.0M | $2.7M | $2.9M | |
| Operating Income | -$483.4K | -$6.1M | -$7.4M | -$4.4M | -$5.6M | -$4.5M | -$5.8M | |
| Interest Expense | $7.9K | $19.2K | $28.0K | $43.7K | $429.3K | $532.4K | $909.1K | |
| Pretax Income | -$507.7K | -$6.0M | -$7.4M | -$5.2M | -$6.0M | -$3.7M | -$6.2M | |
| Net Income | -$507.7K | -$6.0M | -$7.4M | -$5.2M | -$6.0M | -$3.7M | -$6.2M | |
| EPS (Diluted) | -1.12 | -0.12 | -2.70 | -1.79 | -2.02 | -1.16 | -1.78 | |
| EBITDA | -$494.0K | -$6.0M | -$7.0M | -$4.4M | -$4.7M | -$2.2M | -$4.4M | |
| Shares Out. (M) | 0.46 | 51.92 | 2.60 | 2.90 | 2.98 | 3.20 | 4.30 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.5M | $8.4M | $1.9M | $1.3M | $103.7K | $1.1M | $9.2M | |
| Short-Term Investments | $0.00 | $4.0M | $0.00 | $0.00 | $0.00 | $5.0K | $3.5K | |
| Total Current Assets | $4.6M | $14.3M | $2.4M | $2.4M | $1.2M | $1.8M | $9.8M | |
| Total Assets | $6.2M | $23.5M | $16.8M | $16.5M | $14.6M | $15.2M | $18.2M | |
| Total Current Liabilities | $751.8K | $2.2M | $728.2K | $1.6M | $3.2M | $8.5M | $5.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $1.6M | $1.8M | $158.6K | $0.00 | |
| Total Liabilities | $882.7K | $2.4M | $797.7K | $3.3M | $5.0M | $8.7M | $5.8M | |
| Stockholders' Equity | $5.3M | $21.1M | $16.0M | $13.2M | $9.6M | $6.6M | $12.4M | |
| Retained Earnings | -$169.2K | -$6.2M | -$13.4M | -$17.6M | -$23.6M | -$27.3M | -$22.1M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$143.4K | -$6.0M | -$4.6M | -$3.6M | -$4.3M | -$2.6M | -$4.4M | |
| Capital Expenditure | -$754.8K | -$4.9M | -$7.2M | -$804.2K | -$152.4K | -$88.4K | -$103.1K | |
| Free Cash Flow | -$898.3K | -$11.0M | -$11.7M | -$4.4M | -$4.4M | -$2.7M | -$4.5M | |
| Investing Cash Flow | -$754.8K | -$9.2M | -$3.2M | -$706.0K | -$154.0K | -$88.4K | -$103.1K | |
| Financing Cash Flow | $5.4M | $19.2M | $1.2M | $3.8M | $3.2M | $3.8M | $13.6M | |
| Issuance of Stock | $5.4M | $18.9M | $1.3M | $1.8M | $2.0M | $395.0K | $11.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$49.1K | -$111.2K | $1.9M | $958.0K | $3.4M | $2.7M | |
| Stock Based Comp. | $0.00 | $1.3M | $1.0M | $163.5K | $60.1K | $46.4K | $114.1K | |
| Net Change in Cash | $4.5M | $4.0M | -$6.5M | -$543.8K | -$1.2M | $1.0M | $10.2M |
Dilution Tracker
Shares outstanding grew 603.1% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+603.1%
Stock Issuance (TTM)
$11.8M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.46 | 51.92 | 2.60 | 2.90 | 2.98 | 3.20 | 4.30 | |
| Change vs Prior % | — | 11310.9% | -95.0% | 11.6% | 2.9% | 7.2% | 34.3% | |
| Stock Issuance | $5.4M | $18.9M | $1.3M | $1.8M | $2.0M | $395.0K | $11.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $1.3M | $1.0M | $163.5K | $60.1K | $46.4K | $114.1K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 66.8% | -86.7% | 69.5% | -486.4% | -699.1% | |
| Operating Margin % | — | — | -9155.2% | -2419.1% | -1438.8% | -1062.3% | -4327.7% | |
| Net Margin % | — | — | -9106.9% | -2868.5% | -1548.3% | -870.8% | -4611.0% | |
| EBITDA Margin % | — | — | -8708.5% | -2441.5% | -1215.5% | -523.4% | -3250.0% | |
| FCF Margin % | — | — | -14533.3% | -2433.0% | -1137.4% | -636.3% | -3323.1% | |
| ROE % | -9.6% | -28.6% | -45.9% | -39.3% | -63.0% | -56.5% | -84.2% | |
| ROA % | -8.2% | -25.7% | -43.7% | -31.5% | -41.5% | -24.4% | -26.7% | |
| ROIC % | -8.9% | -28.4% | -45.7% | -29.4% | -45.5% | -34.5% | -27.9% | |
| R&D / Revenue % | — | — | 165.1% | 84.0% | 37.1% | 81.6% | 234.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 124.3% | 115.3% | 9.5% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -391.3% | 272.5% | -866.5% | |
| Operating Income | 0.0% | -1152.6% | -22.0% | 40.7% | -28.0% | 19.2% | |
| Net Income | 0.0% | -1085.7% | -22.1% | 29.3% | -16.2% | 38.4% | |
| EPS (Diluted) | 0.0% | 89.3% | -2150.0% | 33.7% | -12.8% | 42.6% | |
| Operating Cash Flow | 0.0% | -4099.0% | 24.0% | 21.4% | -18.9% | 38.6% | |
| Free Cash Flow | 0.0% | -1120.0% | -7.0% | 62.4% | -0.6% | 38.7% | |
| R&D Expense | 0.0% | 0.0% | -44.7% | 14.2% | -5.0% | 141.0% | |
| SG&A Expense | 0.0% | 947.1% | 21.3% | -35.9% | 1.5% | -31.8% | |
| Total Assets | 0.0% | 280.3% | -28.3% | -1.9% | -11.8% | 4.7% | |
| Book Value / Share | 0.0% | -96.5% | 1419.7% | -26.1% | -29.6% | -35.9% | |
| Debt | 0.0% | 60.5% | -37.2% | 983.4% | 61.2% | 143.0% | |
| Diluted Shares | 0.0% | 11310.9% | -95.0% | 11.6% | 2.9% | 7.2% |
Valuation
P/E (TTM)At Loss
P/S106.58
10Y Low / Med / High56.53 / 86.52 / 289.72
P/B0.80
10Y Low / Med / High1.19 / 2.30 / 46.86
EV/EBITDAAt Loss
EV/Revenue61.48
10Y Low / Med / High63.33 / 99.47 / 268.28
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$4.10
Net Current Assets / Share
$1.00
Graham Net-Net
$1.17
Cash / Share
$3.04
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -20.06 | -158.45 | -3.33 | -3.02 | -3.66 | -9.95 | -1.67 | |
| P/S Ratio | 0.00 | 0.00 | 289.72 | 86.52 | 56.53 | 86.48 | 106.58 | |
| P/B Ratio | 1.93 | 46.86 | 1.46 | 1.19 | 2.30 | 5.61 | 0.80 | |
| EV/EBITDA | -11.96 | -164.46 | -3.08 | -3.63 | -5.21 | -19.00 | -2.19 | |
| EV/Revenue | 0.00 | 0.00 | 268.28 | 88.52 | 63.33 | 99.47 | 61.48 |
Analyst Estimates & Quality
Altman Z-Score
-0.41
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 |
|---|---|
| Revenue | $1.2M |
| Net Income | -$2.0M |
| EPS | $-0.64 |
| # Analysts (EPS) | 1 |